DJIA 17,522.80 -167.06 -0.94%
NASDAQ 5,100.46 -27.82 -0.54%
S&P 500 2,089.13 -14.71 -0.70%
market minute promo

Seattle Genetics (NASDAQ: SGEN)

46.29 -1.58 (-3.30%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

SGEN $46.29 -3.30%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $47.66
Previous Close $47.87
Daily Range $45.76 - $48.00
52-Week Range $30.05 - $52.33
Market Cap $5.8B
P/E Ratio -53.79
Dividend (Yield) $0.00 (0.0%)
Volume 669,232
Average Daily Volume 898,006
Current FY EPS -$0.80

Sector

Healthcare

Industry

Drug Makers

Seattle Genetics (SGEN) Description

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Website: http://www.seattlegenetics.com/

News & Commentary

Still Profitless in Seattle Genetics

But a growth opportunity is around the corner.

Seattle Genetics (SGEN) Loss Widens in Q2, Ups 2015 View - Analyst Blog

Seattle Genetics (SGEN) Clay B. Siegall on Q2 2015 Results - Earnings Call Transcript

Seattle Genetics (SGEN) Q2 2015 Results - Earnings Call Webcast

First Week of SGEN March 2016 Options Trading

How To Make Money In Small To Nano-Cap Biotech

Interesting SGEN Put And Call Options For August 21st

Seattle Genetics' Collaborative Approach To Fighting Cancer Makes It A Buy

Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the Intern

Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma

The Zacks Analyst Blog Highlights: Regeneron, Vertex, Celgene, Seattle Genetics and SAGE Therapeutic

The Zacks Analyst Blog Highlights: Regeneron, Vertex, Celgene, Seattle Genetics and SAGE Therapeutics - Press Releases

See More SGEN News...

SGEN's Top Competitors

SGEN $46.29 (-3.30%)
Current stock: SGEN
AMGN $174.58 (-1.14%)
Current stock: AMGN
GILD $118.74 (0.75%)
Current stock: GILD
BIIB $322.89 (1.29%)
Current stock: BIIB